DEF: TG Therapeutics Seeks Stockholder Approval for Incentive Plan Amendment to Boost Share Issuance

TG Therapeutics is asking stockholders to approve an amendment to its 2022 Incentive Plan, increasing the number of shares authorized for issuance from 17,000,000 to 22,000,000.

Summary

• TG Therapeutics is holding its 2025 Annual Meeting of Stockholders on June 12, 2025.
• Stockholders will vote on several proposals, including the election of six directors, ratification of KPMG LLP as the independent accounting firm, approval of executive compensation, and an amendment to the 2022 Incentive Plan.
• The key proposal involves increasing the number of shares authorized for issuance under the 2022 Incentive Plan from 17,000,000 to 22,000,000.
• The company believes this increase is necessary to continue attracting, retaining, and motivating employees and align their interests with those of stockholders.
• As of April 14, 2025, there were 158,776,296 shares of common stock outstanding.
• As of April 14, 2025, 1,711,058 shares remain available for issuance under the 2022 Incentive Plan.
• The company's three-year average burn rate was 3.4% for the years ended December 31, 2024, 2023 and 2022.
• The company's overhang as of April 14, 2025 was 8.5% and would increase to 11.6% if the amendment is approved.

Sentiment

Score: 7

Explanation: The document is primarily factual and related to corporate governance. The proposed amendment to the incentive plan is a positive sign of growth and the need to incentivize employees, but also introduces potential dilution.

Positives

• The proposed amendment to the 2022 Incentive Plan is intended to align the interests of employees, officers, directors, and consultants with those of the stockholders.
• The company has a clawback policy in place for incentive-based compensation.
• The company prohibits the repricing of stock options without stockholder approval.
• The company does not offer tax gross-ups to its NEOs.
• The company's 2024 BRIUMVI U.S. net product revenue was $310 million, representing approximately 250% growth year over year.
• The company launched a Phase 1 trial evaluating subcutaneous ublituximab in patients with relapsing forms of multiple sclerosis (MS).
• The company entered into a global license agreement with Precision BioSciences, Inc. (Precision) for the development and commercialization of Precisions allogeneic CD19 CAR T therapy program, azercabtagene zapreleucel (azer-cel), for the treatment of autoimmune disorders and launched a Phase 1 trial in primary progressive multiple sclerosis.

Negatives

• At the 2024 Annual Meeting of Stockholders, approximately 57.7% of the shares represented and entitled to vote at the annual meeting voted to approve the compensation of the Company's NEOs, as discussed and disclosed in the 2024 Proxy Statement.

Risks

• If the proposed amendment to increase the share reserve is not approved, the company may face challenges in attracting and retaining talent.
• The company's success depends on the continued contributions of its key personnel.
• The company's future performance is subject to various risks, including those related to drug development, regulatory approvals, and commercialization.

Future Outlook

The company intends to continue utilizing the 2022 Incentive Plan (as amended by the Amendment) to grant stock-based awards to its officers, employees, directors and consultants in order to recruit, incentivize, retain and reward those who are critical to its success.

Industry Context

The document relates to executive compensation and corporate governance, which are standard topics for publicly traded companies in the biopharmaceutical industry. The use of equity-based compensation is common to align the interests of management with those of shareholders.

Comparison to Industry Standards

• The Compensation Committee benchmarks against a peer group of public companies with similar characteristics, including Acadia Pharmaceuticals, Inc., CRISPR Therapeutics AG, PTC Therapeutics, Inc., Agios Pharmaceuticals, Inc., Deciphera Pharmaceuticals, Inc., Rhythm Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Denali Therapeutics, Inc., Twist Bioscience Corporation, Apellis Pharmaceuticals, Inc., Geron Corporation, Ultragenyx Pharmaceutical, Inc., Blueprint Medicines Corporation, Iovance Biotherapeutics, Inc., Vericel Corporation, Corcept Therapeutics Incorporated, Madrigal Pharmaceuticals, Inc., Xenocor, Inc..
• The company's three-year average burn rate was 3.4% for the years ended December 31, 2024, 2023 and 2022.
• The company's overhang as of April 14, 2025 was 8.5% and would increase to 11.6% if the amendment is approved.

Related Party Transactions

• The company has an Office Agreement with Fortress Biotech, Inc. (FBIO), where Mr. Weiss, the Chairman and Chief Executive Officer of TG Therapeutics, also serves as a director and Executive Vice Chairman, Strategic Development.
• The company has a Shared Services Agreement with FBIO to share the cost of certain services.
• The company has a Global Collaboration Agreement with Checkpoint Therapeutics, Inc. (Checkpoint), a subsidiary of FBIO, where Mr. Weiss also serves as Chairman of the board of directors.

Stakeholder Impact

• Approval of the incentive plan amendment could positively impact employees by providing them with equity-based compensation.
• Stockholders may experience dilution if the amendment is approved, but the company believes it is necessary for long-term growth.
• The company's performance and strategic decisions impact its employees, customers, suppliers, and creditors.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 12, 2025.
• The company will implement the approved proposals, including the amendment to the 2022 Incentive Plan.

Key Dates

Keywords

incentive plan, stockholders, compensation, directors, executive officers, shares, TG Therapeutics, Briumvi, Ublituximab, Amendment